PD-L1
Mouse Recombinant Cd274 - Fc Tagged
Reference ID:KB-3840
Western Blot
ELISA
FACS
Protein:Protein
Flow Cytometry
Gene of Interest
Gene Synonyms:Cd274;B7h1;Pdcd1l1;Pdcd1lg1;Pdl1
Protein Names:Programmed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligand 1) (B7 homolog 1) (B7-H1) (CD antigen CD274)
Accession Data
Organism:Mus musculus (Mouse)
Mass (kDa):327.80
Length (aa):290
Sequence:MRIFAGIIFTACCHLLRAFTITAPKDLYVVEYGSNVTMECRFPVERELDLLALVVYWEKEDEQVIQFVAGEEDLKPQHSNFRGRASLPKDQLLKGNAALQITDVKLQDAGVYCCIISYGGADYKRITLKVNAPYRKINQRISVDPATSEHELICQAEGYPEAEVIWTNSDHQPVSGKRSVTTSRTEGMLLNVTSSLRVNATANDVFYCTFWRSQPGQNHTAELIIPELPATHPPQNRTHWVLLGSILLFLIVVSTVLLFLRKQVRMLDVEKCGVEDTSSKNRNDTQFEET
Proteomics (Proteome ID):UP000000589
Proteomics (Chromosome): Chromosome 19
Function [CC]:Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:11015443, PubMed:12719480). {ECO:0000269|PubMed:11015443, ECO:0000269|PubMed:11238124, ECO:0000269|PubMed:12719480}.; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:12218188, PubMed:27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:12218188). {ECO:0000269|PubMed:12218188, ECO:0000269|PubMed:27281199}.
Induction:Up-regulated by IFNG treatment in monocytes. Up-regulated on dendritic cells, B-cells and macrophages after activation by LPS and IFNG. {ECO:0000269|PubMed:11015443, ECO:0000269|PubMed:11238124}.
Tissue Specificity:Highly expressed in the heart, thymus, skeletal muscle, and lung. Weakly expressed in the kidney, spleen, thyroid, and liver. Expressed on activated dendritic cells, B-cells and macrophages. Expressed in numerous tumor cells lines of lymphoid origin. {ECO:0000269|PubMed:11015443, ECO:0000269|PubMed:11224527, ECO:0000269|PubMed:11238124}.
Mutagenesis:MUTAGEN 27 27 L->A: PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 31 31 E->S: Significantly reduces the binding to PDCD1. {ECO:0000269|PubMed:12719480}.; MUTAGEN 34 34 S->Y: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 37 37 T->Y: Significantly reduces the binding to PDCD1. {ECO:0000269|PubMed:12719480}.; MUTAGEN 49 49 D->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 56 56 Y->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 58 58 E->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 62 62 E->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 67 67 F->A: Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells. {ECO:0000269|PubMed:12719480}.; MUTAGEN 69 69 A->F: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 72 72 E->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 75 75 K->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 89 89 K->S: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 98 98 A->F: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 100 100 Q->S: No effect on PDCD1 binding.; MUTAGEN 113 113 C->Y: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 115 115 I->A: Abolishes the binding to PDCD1. {ECO:0000269|PubMed:12719480}.; MUTAGEN 117 117 S->Y: No effect on PDCD1 binding. {ECO:0000269|PubMed:12719480}.; MUTAGEN 124 124 K->A: Abolishes the binding to PDCD1. {ECO:0000269|PubMed:12719480}.; MUTAGEN 126 126 I->A: Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells. {ECO:0000269|PubMed:12719480}.; MUTAGEN 129 129 K->S: Abolishes the binding to PDCD1. {ECO:0000269|PubMed:12719480}.
Reagent Data
Name:PD-L1
Class:Immune Checkpoint
Subcategory:Protein
Region:Phe 19 - Thr 238
Molecular Weight:51.8
Source:HEK293
Species:Mouse
Tag:Fc
Format:Lyophilized
Purification System:Chromatography
Formulation:Sterile-filtered colorless solution
Formulation Concentration:1 mg/ml
Buffer Volume:Standard
Buffer Solution:PBS
pH:7.4-7.5
Toxicity
Endotoxin Level:< 1%
Aggregate Tested By:SDS-PAGE
Endotoxin Screened:< 0.1 ng/ug
Purity:> 98%
Determined: SDS-PAGE
Stain:Blue
Chromotography:Anion-exchange
Validated: RP-HPLC
Sample Handling
Storage:-20°C
Stability:This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.
Preparation:Reconstitute in sterile distilled H2O to no less than 100 ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.